Signing Payment. In partial consideration for the acquisition of license rights under the Theravance Patents and the Theravance Know-How by GSK under this Agreement, GSK shall on the Effective Date, pay to Theravance a non-creditable, non-refundable amount of Ten Million United States Dollars (U.S. $10,000,000).
Appears in 4 contracts
Sources: Collaboration Agreement (Theravance Inc), Collaboration Agreement (Theravance Inc), Collaboration Agreement (Theravance Inc)